199 related articles for article (PubMed ID: 26501510)
1. Emixustat and Lampalizumab: Potential Therapeutic Options for Geographic Atrophy.
Jack LS; Sadiq MA; Do DV; Nguyen QD
Dev Ophthalmol; 2016; 55():302-9. PubMed ID: 26501510
[TBL] [Abstract][Full Text] [Related]
2. Emixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Clinical Trial.
Rosenfeld PJ; Dugel PU; Holz FG; Heier JS; Pearlman JA; Novack RL; Csaky KG; Koester JM; Gregory JK; Kubota R
Ophthalmology; 2018 Oct; 125(10):1556-1567. PubMed ID: 29716784
[TBL] [Abstract][Full Text] [Related]
3. Phase ii, randomized, placebo-controlled, 90-day study of emixustat hydrochloride in geographic atrophy associated with dry age-related macular degeneration.
Dugel PU; Novack RL; Csaky KG; Richmond PP; Birch DG; Kubota R
Retina; 2015 Jun; 35(6):1173-83. PubMed ID: 25932553
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials.
Holz FG; Sadda SR; Busbee B; Chew EY; Mitchell P; Tufail A; Brittain C; Ferrara D; Gray S; Honigberg L; Martin J; Tong B; Ehrlich JS; Bressler NM;
JAMA Ophthalmol; 2018 Jun; 136(6):666-677. PubMed ID: 29801123
[TBL] [Abstract][Full Text] [Related]
5. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration.
Yaspan BL; Williams DF; Holz FG; Regillo CD; Li Z; Dressen A; van Lookeren Campagne M; Le KN; Graham RR; Beres T; Bhangale TR; Honigberg LA; Smith A; Henry EC; Ho C; Strauss EC;
Sci Transl Med; 2017 Jun; 9(395):. PubMed ID: 28637922
[TBL] [Abstract][Full Text] [Related]
6. Complement inhibition as a therapeutic strategy in retinal disorders.
Kassa E; Ciulla TA; Hussain RM; Dugel PU
Expert Opin Biol Ther; 2019 Apr; 19(4):335-342. PubMed ID: 30686077
[TBL] [Abstract][Full Text] [Related]
7. A mechanistic pharmacokinetic/pharmacodynamic model of factor D inhibition in cynomolgus monkeys by lampalizumab for the treatment of geographic atrophy.
Le KN; Gibiansky L; Good J; Davancaze T; van Lookeren Campagne M; Loyet KM; Morimoto A; Jin J; Damico-Beyer LA; Hanley WD
J Pharmacol Exp Ther; 2015 Nov; 355(2):288-96. PubMed ID: 26359312
[TBL] [Abstract][Full Text] [Related]
8. Phase 1, dose-ranging study of emixustat hydrochloride (ACU-4429), a novel visual cycle modulator, in healthy volunteers.
Kubota R; Al-Fayoumi S; Mallikaarjun S; Patil S; Bavik C; Chandler JW
Retina; 2014 Mar; 34(3):603-9. PubMed ID: 24056528
[TBL] [Abstract][Full Text] [Related]
9. Visual Function Decline Resulting from Geographic Atrophy: Results from the Chroma and Spectri Phase 3 Trials.
Heier JS; Pieramici D; Chakravarthy U; Patel SS; Gupta S; Lotery A; Lad EM; Silverman D; Henry EC; Anderesi M; Tschosik EA; Gray S; Ferrara D; Guymer R;
Ophthalmol Retina; 2020 Jul; 4(7):673-688. PubMed ID: 32199866
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules.
Nebbioso M; Lambiase A; Cerini A; Limoli PG; La Cava M; Greco A
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987401
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy of retinal disease with visual cycle modulators.
Hussain RM; Gregori NZ; Ciulla TA; Lam BL
Expert Opin Pharmacother; 2018 Apr; 19(5):471-481. PubMed ID: 29542350
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Options Under Development for Nonneovascular Age-Related Macular Degeneration and Geographic Atrophy.
Kim JB; Lad EM
Drugs Aging; 2021 Jan; 38(1):17-27. PubMed ID: 33355716
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 Study of the Anti-HtrA1 Antibody-binding Fragment FHTR2163 in Geographic Atrophy Secondary to Age-related Macular Degeneration.
Khanani AM; Hershberger VS; Pieramici DJ; Khurana RN; Brunstein F; Ma L; Maass KF; Honigberg LA; Tom I; Chen H; Strauss EC; Lai P;
Am J Ophthalmol; 2021 Dec; 232():49-57. PubMed ID: 34214452
[TBL] [Abstract][Full Text] [Related]
14. Complement inhibition in cynomolgus monkeys by anti-factor d antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration.
Loyet KM; Good J; Davancaze T; Sturgeon L; Wang X; Yang J; Le KN; Wong M; Hass PE; van Lookeren Campagne M; Haughney PC; Morimoto A; Damico-Beyer LA; DeForge LE
J Pharmacol Exp Ther; 2014 Dec; 351(3):527-37. PubMed ID: 25232192
[TBL] [Abstract][Full Text] [Related]
15. Maximum Reading Speed in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Varma R; Souied EH; Tufail A; Tschosik E; Ferrara D; Zhang J; Silverman D; Dolan C; Bressler NM
Invest Ophthalmol Vis Sci; 2018 Mar; 59(4):AMD195-AMD201. PubMed ID: 30383205
[TBL] [Abstract][Full Text] [Related]
16. Investigational drugs inhibiting complement for the treatment of geographic atrophy.
Ferro Desideri L; Artemiev D; Bernardi E; Paschon K; Zandi S; Zinkernagel M; Anguita R
Expert Opin Investig Drugs; 2023; 32(11):1009-1016. PubMed ID: 37902056
[TBL] [Abstract][Full Text] [Related]
17. Latest Developments in the Management of AMD.
Chang A; Schlottmann PG; Chan RVP
Asia Pac J Ophthalmol (Phila); 2017; 6(6):477-478. PubMed ID: 29204992
[No Abstract] [Full Text] [Related]
18. Protective effect of RIPK1-inhibitory compound in in vivo models for retinal degenerative disease.
Jang KH; Do YJ; Koo TS; Choi JS; Song EJ; Hwang Y; Bae HJ; Lee JH; Kim E
Exp Eye Res; 2019 Mar; 180():8-17. PubMed ID: 30500363
[TBL] [Abstract][Full Text] [Related]
19. Hot Topics in Dry AMD.
Narayanan R; Kuppermann BD
Curr Pharm Des; 2017; 23(4):542-546. PubMed ID: 28003009
[TBL] [Abstract][Full Text] [Related]
20. Nonneovascular Age-Related Macular Degeneration.
Michels S; Garhöfer G
Dev Ophthalmol; 2016; 55():112-24. PubMed ID: 26502209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
